Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Recruiting 11Not yet recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Genitourinary 4Breast 2Tumor-Agnostic 1Thoracic 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16trastuzumab deruxtecan 15Docetaxel 15Radiotherapy 13Standard of Care 12Fulvestrant 12Drug Therapy 12dalpiciclib 11Letrozole 11pembrolizumab 9Epirubicin 9sacituzumab govitecan 8palbociclib 8exemestane 8eribulin 8Anastrozole 8Injections 7Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Specimen Handling 6Neoadjuvant Therapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × disitamab vedotin × Breast × Clear all
NCT07366840 2026-01-26

BRIGHT

Fudan University

Phase 2/3 Not yet recruiting
268 enrolled
Breast

Breast Neoplasms

NCT06015113 2023-08-29

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

Xi'an International Medical Center Hospital

Phase NA Not yet recruiting
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡